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Summary
Tumorigenesis is a multistep process characterized by
a myriad of genetic and epigenetic alterations. Identi-
fying the causal perturbations that confer malignant
transformation is a central goal in cancer biology. Here
we report an RNAi-based genetic screen for genes
that suppress transformation of human mammary ep-
ithelial cells. We identified genes previously impli-
cated in proliferative control and epithelial cell func-
tion including two established tumor suppressors,
TGFBR2 and PTEN. In addition, we uncovered a pre-
viously unrecognized tumor suppressor role for REST/
NRSF, a transcriptional repressor of neuronal gene
expression. Array-CGH analysis identified REST as a
frequent target of deletion in colorectal cancer. Fur-
thermore, we detect a frameshift mutation of the REST
gene in colorectal cancer cells that encodes a domi-
nantly acting truncation capable of transforming epithe-
lial cells. Cells lacking REST exhibit increased PI(3)K
signaling and are dependent upon this pathway for their
transformed phenotype. These results implicate REST
as a human tumor suppressor and provide a novel ap-
proach to identifying candidate genes that suppress the
development of human cancer.*Correspondence: selledge@genetics.med.harvard.edu
7 These authors contributed equally to this work.Introduction
The evolution of human cells into malignant derivatives
is driven by the aberrant function of genes that posi-
tively and negatively regulate various aspects of the
cancer phenotype, including altered responses to mito-
genic and cytostatic signals, resistance to programmed
cell death, immortalization, neoangiogenesis, and inva-
sion and metastasis (Hanahan and Weinberg, 2000).
The integrity of these gene functions is compromised
by substantial genetic and epigenetic alterations ob-
served in most cancer cell genomes. To understand the
tumorigenic process, it is imperative to identify and
characterize the genes that provide tumor cells with the
capabilities requisite for their initiation and progression.
However, the identities of those genes that contribute
to the tumor phenotype are often concealed by the fre-
quent alterations in genes that play no role in tumori-
genesis.
Identifying genes that restrain tumorigenesis (tumor
suppressors) has proven especially challenging due to
their recessive nature. Further complicating their dis-
covery are the multifaceted mechanisms by which tu-
mor suppressor genes are inactivated, including changes
in copy number and structure, point mutations, and epi-
genetic alterations (Balmain et al., 2003). Moreover, the
mechanisms by which tumor suppressor genes are in-
hibited may vary between tumors. With this in mind, a
variety of molecular and cytogenetic technologies has
been used to establish extensive catalogs of genetic
alterations within human cancers (Albertson et al.,
2003; Futreal et al., 2004). And while it is generally ac-
cepted that highly recurrent aberrations signify changes
that are important for tumor development, the causal
perturbations underlying tumor genesis are often con-
founded by the extensive size of alterations and the
large number that are incidental to the tumor pheno-
types. As such, new strategies to delineate genes with
functional relevance to tumor initiation and develop-
ment are essential to understanding these processes.
One approach to this problem involves the use of in
vitro models of human cell transformation. In such
models, primary cells are transformed into tumorigenic
derivatives by the coexpression of cooperating onco-
genes (Elenbaas et al., 2001; Hahn et al., 1999; Zhao et
al., 2004). These experimental models have been useful
in delineating the minimum genetic perturbations re-
quired for transformation of various human cell types
as well as evaluating the functional cooperation be-
tween a gene of interest and a defined genetic context.
To date, these models of human cell transformation
have incorporated genes already implicated in human
tumorigenesis. However, such models also provide a
potentially useful platform for the identification of new
pathways that contribute to the transformed phe-
notype.
The emergence of RNA interference (RNAi) as a
mechanism to silence gene expression has enabled
loss-of-function analysis in mammalian cells in a poten-
tially genomewide manner (Berns et al., 2004; Paddison
Cell
838et al., 2004). We have utilized such an RNAi-based, for- P
dward genetic approach to identify genes that suppress
moncogenic transformation in a defined human mam-
Hmary epithelial cell model. We identified approximately
25 potential suppressors of epithelial cell transfor-
tmation (SECT) genes that represent candidate tumor
Tsuppressors. Several are associated with known can-
vcer-relevant pathways including Ras, PI(3)K, and TGF-β
Tsignaling. In addition, we provide evidence that one of
tthese candidates, the transcriptional repressor REST/
uNRSF, plays a previously unappreciated role in tumor
Tsuppression. These findings support the utility of this





lRNAi Screen for Suppressors
sof Epithelial Cell Transformation
pRecently, several cell culture models of human cell
ptransformation have been described in which primary
phuman cells are engineered to express combinations
lof dominantly acting cellular and viral oncogenes and
Tsubsequently measured for anchorage-independent
wproliferation, an in vitro hallmark of transformation
c(Elenbaas et al., 2001; Hahn et al., 1999; Zhao et al., 2004).
dWe sought to identify short-hairpin RNAs (shRNAs) that
mcooperate within the context of such a model. As >80%
sof cancers arise from epithelial tissues, we chose to
sexamine cells derived from human mammary epithelial
rcells (HMECs) to increase the probability of finding
ogenes with relevance to epithelial cancers. The cells
rutilized for this screen (referred to as TLM-HMECs)
awere created by sequentially introducing the human tel-
comerase catalytic subunit (hTERT) and the large T-anti-
a
gen (LT) of SV40 into HMECs (Zhao et al., 2003). In addi-
q
tion, these cells exhibit elevated expression of the
b
endogenous c-myc gene resulting from extended cul-
ture in vitro (Wang et al., 2000). Important to the efficacy g
of this screen, these cells do not proliferate in the ab- d
sence of extracellular matrix (<1 colony in 104; Figure t
1B, left panel) (Zhao et al., 2003). Recent experiments c
have demonstrated that hyperactivation of the PI(3)K g
pathway by ectopic expression of a PI(3)K mutant en- t
dows these cells with the ability to proliferate in an i
anchorage-independent manner (Zhao et al., 2003), w
suggesting that TLM-HMECs are susceptible to trans- c
formation by a single genetic event. However, since re- G
cent evidence suggests that overexpressed oncogenes n
can confer different biological effects than oncogenes a
expressed at endogenous levels (Guerra et al., 2003; f
Tuveson et al., 2004), we sought to determine whether δ
disruption of endogenous PI(3)K regulation is sufficient i
to elicit transformation. To this end, an shRNA directed e
against the PTEN tumor suppressor was introduced t
into TLM-HMECs by retroviral-mediated gene transfer. g
PTEN catalyzes the removal of the 3-position phosphate c
from PtdIns(3,4,5)P3 and is a well-characterized antag- t
onist of PI(3)K-dependent signals (Vivanco and Sawyers,
2002). PTEN-specific shRNA significantly reduced PTEN s
expression (Figure 1A). Importantly, reduced PTEN ex- g
pression conferred robust anchorage-independent pro- o
liferation to a level similar to an activated mutant ofI(3)K (myr-p110α) (Figure 1B, right panel), thereby vali-
ating that RNAi-mediated loss of function of this tu-
or suppressor is capable of transforming TLM-
MECs.
To identify endogenous suppressors of epithelial cell
ransformation (SECT) genes (Figure 1C), we infected
LM-HMECs with a retroviral shRNA library we pre-
iously constructed in pSM1 (Paddison et al., 2004).
his library consists of 28,000 sequence-verified shRNAs
argeting w9,000 genes, with each shRNA linked to a
nique 60 nucleotide sequence (DNA “barcode”).
hese molecular barcodes can be used to monitor rela-
ive frequencies of individual shRNAs in complex pop-
lations via microarray technology (Hensel et al., 1995).
LM-HMECs infected with a control retrovirus or pSM1
ibrary were assessed for anchorage-independent pro-
iferation (Figure 1C). Only cells infected with the pSM1
ibrary exhibited formation of macroscopic colonies in
emisolid media (Figure 1D, right panels), indicating the
resence of shRNAs that transform TLM-HMECs. Ap-
roximately 100 anchorage-independent clones were
ooled and analyzed for the enrichment of barcodes
inked to the individual shRNAs (Figure 1D, left panel).
o support the results from the hybridization studies,
e sequenced approximately 200 individual an-
horage-independent clones isolated from pSM1 trans-
uctants (including 70 colonies used for the barcode
icroarray hybridization). Sequencing of the proviral
hRNAs from these colonies identified 25 unique
hRNAs. Importantly, these approaches yielded similar
esults, with 18 of the 25 genes revealed by sequencing
f individual clones also identified by barcode microar-
ay analysis (see Table S1 in the Supplemental Data
vailable with this article online). This is the first appli-
ation of the barcode approach in a mammalian screen,
nd the high correspondence of identities with the se-
uenced clones indicates that such an approach har-
ors promise in more complex experimental designs.
Most of the shRNAs identified in this screen target
enes known or predicted to function in signal trans-
uction or transcriptional regulation (Table 1), consis-
ent with the role of these gene classes in regulating
omplex cell behaviors. While the majority of these
enes have not been directly examined for their rela-
ionship to cancer pathogenesis, several are implicated
n the regulation of cancer-relevant pathways. Notably,
e identified an shRNA targeting CAPRI (RASA4), a cal-
ium-sensing Ras GTPase-activating protein (Ras-
AP) previously shown to inhibit Ras-dependent sig-
aling (Lockyer et al., 2001). This is consistent with the
bility of a constitutively active Ras mutant to trans-
orm TLM-HMECs (J.J.Z. and T.R., unpublished data).
-catenin (CTNND2) and K-cadherin (CDH6) were also
solated (Table 1), suggesting a potential role for adher-
ns junctions in preventing epithelial cell transforma-
ion. Strikingly, the type II receptor for transforming
rowth factor-β (TGF-β) was also identified, thus impli-
ating the TGF-β tumor suppressor pathway in the con-
rol of epithelial cell transformation (see below).
The vast majority (90%) of colonies analyzed in this
creen represented shRNAs directed against eight
enes (demarcated in Table 1). Therefore, we focused
ur subsequent investigations on the gene targets ofthese frequently isolated and potentially more pene-
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839Figure 1. Identification of Suppressors of Epithelial Cell Transformation
(A) Cell lysates from TLM-HMECs expressing control or PTEN-shRNAs were immunoblotted for expression of PTEN. The asterisk denotes a
crossreacting band that serves as a loading control.
(B) Cells from (A) were cultured in semisolid media for 3 weeks and photographed at 20× (top panels) or 1× (bottom panels) magnification.
Quantitation of macroscopic colony (>0.2 mm) formation in semisolid media by TLM-HMECs transduced with empty retrovirus or virus
encoding control shRNA, myr-p110α cDNA, or PTEN-shRNA.
(C) Outline of the transformation screen. Details provided in Experimental Procedures.
(D) TLM-HMECs transduced with empty or pSM1-shRNA library and cultured in semisolid media for 3 weeks, photographed at 20× (top
panels). Bottom panel illustrates a section of a barcode microarray. Barcodes were PCR amplified from genomic DNA isolated from a pool of
100 anchorage-independent colonies. cRNA was transcribed from a total library preparation (red channel, 635 nm) or from PCR-amplified
barcode (green channel, 532 nm) and hybridized to a barcode microarray. Enriched barcodes (green/yellow) are indicated by arrows.
(E) TLM-HMECs expressing shRNAs targeting candidate genes (two independent shRNAs per gene target) were cultured in semisolid media
and quantitated for formation of macroscopic colonies. Experiments were performed in triplicate.trant shRNAs. In order to validate putative gene targets,
we assessed the transforming potential of shRNAs tar-
geting different regions of each candidate. Parental
TLM-HMECs were transduced with shRNA-encoding
retroviruses and measured for anchorage-independent
proliferation. Importantly, for five of six candidate genes
tested, two shRNAs transformed TLM cells (Figures 1Eand 2B, and data not shown), indicating that the ob-
served phenotype was most likely attributable to re-
duced function of the intended target and not caused
by off-target effects. In contrast, two independent shRNAs
directed against the pseudogene VDAC2P did not reca-
pitulate transforming potential of the library-derived
VDAC2P-shRNA (data not shown), implying that these
Cell
840Table 1. Suppressors of Epithelial Cell Transformation
Gene Previously Known Functions Validated
CDH6* Type II cadherin; cell-cell adhesion +
CTNND2* Stabilization of adherens junctions +
INPP4B* PIP2 phosphatase ND
RASA4* Ras GAP; calcium-responsive inhibitor of Ras signaling ND
REST* Transcriptional repression of neural genes +
TGFBRII* TGF-β signaling; cytostatic and apoptotic programs in epithelial tissues +
VDAC2P* None −
ZNF134* None +
BCL9 WNT/β-catenin signaling ND
MAP4K4 TNFα signaling; JNK activation ND
PKN2 Rho signaling; Akt inhibition ND
BDKRB2 G protein-coupled receptor ND
LMO4 Transcriptional regulation; mammary gland development ND
HAND1 Transcriptional regulation; cardiac morphogenesis ND
AKT2 PI(3)K effector; survival signaling ND
STAG3 Meiosis cohesion ND
DUT dUTP pyrophosphatase ND
RPP30 tRNA processing ND
This table lists gene targets of unique, sequence-verified shRNAs identified in 200 anchorage-independent colonies isolated from the screen.
shRNAs identified in the context of double integrations (seven in total) were disregarded. Ninety percent of isolated anchorage-independent
colonies encoded one of eight shRNAs (demarcated by *). For candidate validation, multiple shRNAs directed against independent sequences
within a gene target were tested for transformation (ND, not determined).shRNAs did not alter VDAC2P expression or that the
nlibrary-derived shRNA targeted the expression of other
genes underlying the transformed phenotype. Consis- T
atent with the latter hypothesis, VDAC2P expression was
undetectable in TLM-HMECs (data not shown). p
w
dEndogenous TGF- Signaling Suppresses
nCellular Transformation
aAs negative regulators of oncogenic transformation,
fgenes isolated in this screen may represent candidate
ttumor suppressor genes or impinge upon pathways
ncritical to the genesis of cancer. Notably, this approach
aidentified the transforming growth factor-β receptor II
m(TGF-βRII) as a regulator of transformation (Table 1).
cObservations in mouse models and in human tumors
kindicate that TGF-βRII (as well as several components
tof TGF-β signaling) is a potent tumor suppressor in nu-
omerous tissues including the mammary and colonic ep-
lithelia (Derynck et al., 2001; Siegel and Massague,
t2003). The TGF-β pathway is a potent inhibitor of epi-
lthelial cell proliferation but has not been previously im-
aplicated in regulating oncogenic transformation in vitro.
tTo verify the role of TGF-βRII in suppression of trans-
tformation, two retroviral-encoded shRNAs targeting in-
tdependent sequences within TGF-βRII were introduced
into TLM-HMECs. These shRNAs reduced TGF-βRII ex-
pression levels and impaired phosphorylation of I
CSMAD2, a substrate and transducer of endogenous
TGF-β receptor signaling (Figure 2A). Importantly, TGF- f
sβRII-targeted shRNAs also elicited robust anchorage-
independent proliferation in TLM cells (Figure 2B), thus t
ovalidating the identification of TGF-βRII in our screen.
Reduced TGF-β signaling did not alter proliferation on R
(an adhesive cell culture surface (Figure 2C), suggesting
that loss of extracellular matrix (ECM) interactions may i
sinduce TGF-β signaling or alter the threshold of endog-
enous TGF-β signaling necessary to elicit a cytostatic h
response.To further examine the role of endogenous TGF-β sig-
aling in restraining cell transformation, we inhibited
GF-β signal transduction by alternative mechanisms
nd assessed the consequences on anchorage-inde-
endent proliferation. TLM-HMECs were transduced
ith retroviruses encoding a previously characterized
ominant-negative mutant of TGF-βRII or SMAD7, a
egative regulator of TGF-β receptor signaling (Siegel
nd Massague, 2003). Expression of either cDNA con-
erred growth in semisolid media (Figure 2D), indicating
hat the transforming capacity of TGF-βRII shRNAs is
ot an RNAi-specific phenomenon. Conversely, ectopic
ctivation of TGF-β signaling by a constitutively active
utant of TGF-βRI (T204D) was able to restrain an-
horage-independent proliferation elicited by PTEN
nockdown (Figure 2E), suggesting a genetic interac-
ion between PI(3)K and TGF-β signaling in the context
f cell transformation. This observation is interesting in
ight of evidence from several systems demonstrating
hat TGF-β and PI(3)K signals are integrated at multiple
evels to regulate survival and proliferation (Conery et
l., 2004; Remy et al., 2004; Seoane et al., 2004). Fur-
her investigation is required to determine the func-
ional nodes through which these two pathways in-
eract during HMEC transformation.
nactivation of REST in Human Tumors
onsistent with a role in suppressing oncogenic trans-
ormation, four of the SECT genes we identified in the
creen or initial experiments are either established
umor suppressors (TGF-βRII and PTEN) or regulators
f cancer-relevant signaling machinery including the
as protooncogene (RASA4) and cadherin complexes
CTNND2). Therefore, it is probable that other genes
dentified in our screen also represent candidate tumor
uppressors and may be found altered in tumors. A
allmark of tumor suppressor loci is their high fre-quency of loss of heterozygosity (LOH) in tumors. Con-
Tumor Suppressor Screen
841Figure 2. TGF-β Signaling Suppresses Epi-
thelial Cell Transformation
(A) Cell lysates from TLM-HMECs expressing
control or TGF-βRII-shRNAs were immu-
noblotted for expression of TGF-βRII, Ran
(loading control), serine 465/467- phosphor-
ylated SMAD2, or total SMAD2.
(B) Cells from (A) were cultured in semisolid
media for 3 weeks, photographed at 20×,
and quantitated for formation of micro-
scopic colonies.
(C) Growth curves of cells expressing control
(B), or two independent TGF-βRII-shRNAs
(■ or :) grown in monolayer culture.
(D) TLM-HMECs were stably transfected
with empty plasmid (pcDNA3) or plasmid ex-
pressing SMAD7 or transduced with empty
retrovirus (LPC) or retrovirus encoding a
dominant-negative mutant of TGF-βRII
(TGFβRII-CYT). Resulting polyclonal cell
lines were assayed for anchorage-indepen-
dent proliferation.
(E) TLM-HMECs were transduced with con-
trol (LPC) or PTEN-shRNA encoding retrovirus.
PTEN-shRNA expressing cells were subse-
quently infected with empty retrovirus or
virus expressing a constitutively active mu-
tant of TGFβRI (TGFβRI-T204D). Each deriv-
ative cell line was assessed for proliferation
in semisolid media.sequently, we examined whether our candidate genes
reside in genetic loci targeted for such chromosomal
aberrations in human tumors. Array-based comparative
genomic hybridization (aCGH) has evolved into a high-
throughput method for cataloging such copy number
aberrations (CNAs) with high resolution. To this end,
aCGH has been successfully utilized to characterize
genomic alterations in the context of pancreatic adeno-
carcinoma (Aguirre et al., 2004) and more recently used
to define CNAs in a large collection of human colon
tumors and cell lines (E.S.M. and R.D., unpublished
data). As described (Aguirre et al., 2004), overlapping
CNAs from individual colon tumor samples and tumor-
derived cell lines were used to define minimal common
regions (MCRs) of loss or gain. These discrete MCRs
were further prioritized based on parameters of confi-
dence and significance including (1) recurrence in mul-
tiple independent samples, (2) high Log2 ratio of
change (e.g., depth of deletion), (3) focal nature (e.g.,
MCR %2.0 Mb), and (4) MCR encompassing no more
than five annotated genes (Aguirre et al., 2004). From
this analysis, nine high-confidence MCRs of recurrent
focal deletions were identified within the colon cancergenome, in sum representing only 34 annotated genes
(Figure 3A). Consistent with its role in the pathogenesis
of human cancers (Ruas and Peters, 1998), the p16INK4A
tumor suppressor was present within one of these focal
deletions (Figure 3A).
Remarkably, without a priori knowledge of the candi-
date genes listed in Table 1, this genomic approach
identified high-confidence MCRs that included two
highly penetrant candidates from our RNAi screen:
TGFBR2 and REST (Figure 3A). RE1-silencing tran-
scription factor (REST)/neuron-restrictive silencing factor
(NRSF) is a transcriptional regulator best characterized
for its role in repressing neuronal genes including neuro-
trophins and cell-adhesion molecules in nonneuronal
tissues (Chong et al., 1995; Schoenherr and Anderson,
1995). Intriguingly, a variety of human tumors including
those arising in breast, ovary, and lung activate expres-
sion of neuron-specific genes. In some instances, the
inappropriate expression of these neural genes elicits
an autoimmune response that culminates in neurologi-
cal disorders, collectively known as paraneoplastic
neurologic degenerations (PND; see Discussion) (Albert
and Darnell, 2004). Such aberrant neural gene expres-
Cell
842Figure 3. Deletion of REST in Human Tumors
(A) High-confidence recurrent CNAs in colon cancer. Recurring focal CNAs in colon adenocarcinoma and tumor cell derivatives were identified
and prioritized as previously described (Aguirre et al., 2004) with modifications. Each of the identified minimum common regions (MCR)
consists of <2.0 Mb and%5 annotated genes. Peak probe values represent the minimum absolute log2 ratio detected within each MCR. Also
shown are the chromosomal location, the number of NCBI annotated genes residing within the MCR, and candidate tumor suppressor genes
within each MCR. SECT genes are highlighted in blue.
(B) aCGH profiles of chromosome 4 in a primary tumor (19T) and a colon cancer cell line (LS123) showing deletion of a discrete region, with
MCR defined by vertical red lines. Raw data and segmentation analysis are represented by blue circles and red horizontal lines, respectively.
Peak data point for each deletion occurs at the REST probe (indicated by arrows).
(C) Segmentation data of aCGH profiles from each of 42 primary colon tumors and 38 colon tumor-derived cell lines. Chromosomal gain
or loss within a section of chromosome 4 is represented by a color gradient (red, gain; blue, loss). Gray boxes represent uninformative
probe hybridizations.sion suggests that these cancers harbor defects in reg- s
nulators of neuronal programs. Consequently, we inves-
tigated a potential role for REST in human tumor c
lsuppression. Deletions of varying size encompassingthe REST locus on chromosome 4 were detected in aignificant proportion of tumors, with evidence of ge-
etic loss in 14 of 42 primary tumors and in 13 of 38
ell lines (Figure 3C), suggesting that chromosomal de-
etions targeting the REST locus are a frequent event
in colon cancer. Importantly, microdeletions encom-
Tumor Suppressor Screen
843passing the REST gene were detected in a primary tu-
mor specimen (CRC_19T) and a colon cancer cell line
(LS123), thus defining a minimal common region. This
MCR (Figure 3B, top panels) encompasses only five
known genes, with the REST gene residing at the peak
amplitude of each of these focal deletions (Figure 3B,
bottom panels). Collectively, the unbiased identification
of REST as a target of recurrent microdeletions as well
as frequent larger deletions strongly suggests that
REST is targeted for inactivation during colon cancer
pathogenesis.
REST is widely expressed throughout nonneuronal
tissues including the colonic epithelium (Figure S1)
(Chong et al., 1995; Schoenherr and Anderson, 1995).
The above results suggest that loss of REST expression
may confer a selective advantage during the evolution
of tumor cells. This hypothesis predicts that cells with
defective REST function may be sensitive to reconstitu-
tion of REST. We examined this prediction by ectopi-
cally expressing REST in colon cancer cells that have
lost (SW1417) or retain (SW620) endogenous REST ex-
pression (Figure 4A). Exogenous REST expression elic-Figure 4. Aberrant REST Function in Colon
Cancer
(A) REST expression was analyzed in cell ly-
sates from SW620 and SW1417 colon can-
cer cell lines by immunoblotting with anti-
bodies recognizing the C terminus of REST.
(B) SW620 and SW1417 cells were trans-
duced with control or REST-expressing ret-
rovirus, seeded at 5000 cells per dish, and
cultured for 2 weeks under puromycin se-
lection.
(C) Single nucleotide deletion within exon 4
of the REST gene (top schematic) was ob-
served in DLD-1 cells by sequence analysis
(coding exons shown in gray). The premature
termination (indicated by red x, bottom
schematic) results in a protein retaining the
DNA binding domain (DBD) and N-terminal
SIN3 binding domain but lacking the repres-
sor domain responsible for interaction with
CoRest (CBD).
(D) The presence of truncated REST was an-
alyzed by immunoblotting with antibodies
recognizing the N terminus of REST (top
panel) or DDB1 (loading control, middle
panel) against cell lystates from colon can-
cer cell lines. Protein lysates derived from
HMECs transfected with empty vector
(pcDNA3) or vector encoding the frameshift
REST mutant (REST-FS) were probed with
antibodies raised against the N terminus of
REST (bottom panel).
(E) TLM-HMECs transduced with control ret-
rovirus or retroviruses encoding flag-REST
or flag-REST-FS were analyzed for exoge-
nous cDNA expression using flag-specific
antibodies (top panel) or assayed for an-
chorage-independent proliferation (bottom
panel).ited a mild decrease in the proliferation of SW620 coloncancer cells (Figure 4B). In contrast, ectopic REST ex-
pression significantly reduced colony formation in SW1417
cells (>50-fold; Figure 4B), indicating that these cells
are highly dependent on the absence of REST for their
proliferation in vitro. Coupled with the function of REST
in suppressing epithelial cell transformation (Figure 1E),
these data strongly support a role for REST in tumor
suppression.
In order to establish a more causal relationship be-
tween disruption of REST function and tumorigenesis,
we analyzed primary colon tumors and colon tumor cell
lines for the presence of mutations within the REST
coding region. We sequenced exons 2–4 of the REST
gene in a total of 86 colon cancers (48 tumors and 38
cell lines). We identified a single-nucleotide deletion
within REST exon 4 of cells derived from a colorectal
adenocarcinoma (DLD-1) (Figure 4C). This frameshift
mutation results in a premature termination codon in
the center of the coding sequence, yielding a protein
with a predicted size of approximately 85 kDa. This
frameshift mutant, referred to as REST-FS, was de-
tected by N-terminal REST antibodies in lysates from
DLD-1 cells but not those of other colon cancer cell
Cell
844lines (Figure 4D, top panel). To confirm this, the frame- s
nshift mutation was engineered into a Flag-tagged REST
cDNA and stably introduced into cells. Expression of p
ban 85 kDa protein was detected using REST- (Figure
4D, bottom panel) and FLAG-specific antibodies (Fig- i
1ure 4E, top panel).
Tumor cells harboring this frameshift mutation also t
cencoded and expressed a wild-type REST allele (data
not shown). Unfortunately, the primary tumor from which (
athese cells were derived is not available, preventing
analysis to determine whether the frameshift mutation s
soccurred in vivo. However, we hypothesized if expres-
sion of REST-FS was important to the genesis of this g
Scancer, the mutant allele should exhibit dominant-
negative activity. REST-FS lacks the C-terminal repres- h
bsor domain that interacts with CoREST, a corepressor
molecule that mediates transcriptional repression and q
Csilencing by REST (Andres et al., 1999). To determine
if REST-FS displays properties of a dominant-negative d
tprotein, we transduced the HMEC derivative (TLM cells)
used in our initial screen with wild-type or mutant REST m
tand assessed anchorage-independent proliferation. Cells
expressing REST-FS but not wild-type REST exhibited
robust colony formation (Figure 4E, bottom panel). The D
ability of REST-FS to phenocopy the transforming activ-
ity of REST shRNAs strongly suggests that this mutant S
interferes with the functions of endogenous REST that I
restrain epithelial cell transformation. Taken together, p
these data provide strong support for the hypothesis f
that REST is a tumor suppressor in human cells. o
l
tREST Suppresses PI(3)K Signaling
wThe implication that REST is involved in regulating the
ptransformed state of epithelial cells led us to determine
pwhich molecular circuits might be affected by loss of
(REST function. Activation of PI(3)K-dependent signal-
ting by a variety of mechanisms has been shown to con-
tfer transformation in HMECs (Zhao et al., 2003), indicat-
eing that this pathway provides a potent stimulus to the
Htransformed phenotype. Furthermore, deregulation of
aPI(3)K signaling occurs in a wide spectrum of human
ccancers (Vivanco and Sawyers, 2002). As such, we ex-
namined the impact of disrupting REST function (Figure
j5A) on the activation of the PI(3)K pathway. TLM-
tHMECs expressing control or REST-shRNA were de-
bprived of growth factors, restimulated with EGF for vari-
wous times, and subsequently analyzed for activating
cphosphorylation of Akt (serine 473), an essential effec-
ator of PI(3)K signaling. Stimulation of Akt phosphor-
ylation by EGF was enhanced in cells expressing
aREST-shRNA throughout the time course (Figure 5B).
sConsistent with increased signaling downstream of Akt,
vphosphorylation of ribosomal S6 protein and transla-
ttional inhibitor 4E-BP1 was also upregulated in cells ex-
Npressing REST shRNA (Figure 5C). In agreement, recent
experiments have demonstrated that ectopic expres-
sion of eIF-4E (the target of 4E-BP1) confers trans- I
Tformation to mammary epithelial cells and promotes tu-
mor formation in vivo (Avdulov et al., 2004; Wendel et p
aal., 2004). These results indicate that impaired REST
function confers an increase in both the intensity and r
Hduration of PI(3)K-dependent signaling. In order to in-
vestigate whether PI(3)K signaling is required for REST-hRNA-induced transformation, we utilized a domi-
ant-negative mutant of the PI(3)K regulatory subunit
85. This mutant (referred to as p85) has previously
een shown to abolish H-RasV12-induced and SV40 st-
nduced cell transformation (Rodriguez-Viciana et al.,
997; Zhao et al., 2003). TLM-HMECs expressing con-
rol, PTEN-, or REST-shRNAs were transduced with a
ontrol or p85-encoding retrovirus. Expression of p85
Figure 5D, top panel) did not alter growth of cells on
n adhesive cell culture surface (data not shown). Con-
istent with the role of PTEN as an antagonist of PI(3)K
ignaling, p85 abrogated anchorage-independent
rowth of PTEN-shRNA cells (Figure 5D, bottom panel).
imilarly, REST-shRNA-induced transformation was in-
ibited in the presence of p85 (Figure 5D, middle and
ottom panels), indicating that PI(3)K signaling is re-
uired for transformation conferred by loss of REST.
oupled with the aberrant activation of PI(3)K-depen-
ent signals in response to reduced REST expression,
hese results suggest that inhibition of PI(3)K signaling
ight be a mechanism through which REST suppresses
ransformation and tumorigenesis.
iscussion
uppressors of Epithelial Cell Transformation
n this study, we applied an shRNA-based genetic ap-
roach to identify genes suppressing oncogenic trans-
ormation of human epithelial cells. Within the context
f this model, we have identified two previously estab-
ished tumor suppressor genes (PTEN and TGFBR2)
hat actively restrain HMEC transformation. In addition,
e have identified several genes that impinge upon
athways implicated in cancer pathogenesis. For exam-
le, we isolated the calcium-sensing Ras-GAP CAPRI
RASA4), a previously described negative regulator of
he Ras protooncogene (Lockyer et al., 2001). Consis-
ent with a role for regulation of Ras signaling in our
xperimental system, activated Ras can transform TLM-
MECs. Likewise, identification of δ-catenin (CTNND2),
member of the p120 catenin family that regulates
adherin stability and trafficking (Reynolds and Rocz-
iak-Ferguson, 2004), implicates a role for adherens
unctions in constraining transformation of HMEC. No-
ably, disruption of adherens junction components has
een shown to alter several growth-regulatory path-
ays (e.g., β-catenin, PI(3)K) and has been linked to
ancer progression in a variety of tissues (Cavallaro
nd Christofori, 2004; Vasioukhin et al., 2001).
The novelty of this genetic approach is in the unbi-
sed identification of new and unanticipated tumor
uppressor functions. In this regard, our studies pro-
ide significant evidence for the identification of a novel
umor suppressor, the transcriptional repressor REST/
RSF (see below).
nvolvement of REST/NRSF in Human Cancer
ranscription factors often coordinately control com-
lex programs of gene expression during development
nd as such are logical candidates underlying the aber-
ant activation of developmental programs in cancer.
ere, we present several lines of evidence that RESTmay play a role in tumor suppression in humans. First,
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845Figure 5. Loss of REST Function Stimulates PI(3)K Signaling and Requires It for HMEC Transformation
(A) Cell lysates from TLM-HMECs expressing control or REST-shRNAs were immunoblotted for expression of Akt (loading control, bottom
panel) or REST (C-terminal antibody, top panel).
(B) TLM-HMECs expressing control or REST-shRNA were starved in basal media without growth factors for 20 hr and restimulated with 10
ng/mL EGF for indicated times. Cell lysates were immunoblotted with antibodies recognizing p-Akt (ser473) or total Akt. Akt phosphorylation
was measured as a ratio of p-Akt/total Akt and represented as a percentage of phosphorylated Akt at 15 min of EGF stimulation in control-
shRNA cells (control-shRNA,,; REST-shRNA,C).
(C) Cell lysates from (A) were probed with antibodies recognizing p-S70 of 4E-BP1, total 4E-BP1, p-S235 and p-S236 of S6, and total S6
as indicated.
(D) REST loss requires PI3K signaling for transformation. TLM-HMECs expressing control, REST, or PTEN-shRNA were transduced with empty
or p85-expressing retrovirus. Immunoblot analysis of endogenous p85 and exogenous p85 as indicated (top panel). Cells were analyzed
for anchorage-independent proliferation (middle and bottom panels).reduced REST function (mediated by RNAi or expres-
sion of dominant-negative REST) promotes transforma-
tion of human epithelial cells. Conversely, reconstitu-
tion of REST expression elicits a dramatic proliferation
defect in colon cancer cells that have lost endogenous
REST function. Strikingly, an independent aCGH-based
search for genomic loci characterized by recurrent
microdeletions identified the REST locus as a high-con-
fidence target in colorectal cancer. This high-confi-
dence list includes two previously established tumor
suppressors, p16INK4A and TGFβRII (Derynck et al.,
2001; Ruas and Peters, 1998; Siegel and Massague,
2003), the latter of which was also identified as a SECT
gene. In addition, larger deletions encompassing the
REST gene were frequent in colon tumors and tumorcell lines. Furthermore, we isolated a frameshift muta-
tion of the REST coding region in colorectal tumor cells
that displays properties of a dominant negative, trans-
forming human epithelial cells to a level similar to REST
shRNAs. Finally, we show that impaired REST function
enhances the intensity and duration of PI(3)K signaling,
a pathway that is aberrantly activated in many if not all
human cancers (Vivanco and Sawyers, 2002). Impor-
tantly, PI(3)K activity was required for cellular trans-
formation conferred by reduced REST function, indicat-
ing that suppression of PI(3)K signaling may be an
important mechanism underlying the ability of REST to
restrain the transformed state. The mechanism by
which REST inhibits this oncogenic pathway is not yet
clear. REST regulates a complex transcriptional pro-
Cell
846gram and as such may impinge on PI(3)K signaling d
lthrough multiple networks. However, it should be noted
that BDNF and other neurotrophins are among the tran- m
sscriptional targets repressed by REST. BDNF activates
the TrkB receptor and has recently been shown to sup- s
spress anoikis via PI(3)K-dependent pathways (Douma
et al., 2004), providing a plausible mechanism for acti- T
ivation of PI(3)K signaling in the absence of REST. Taken
together, these data provide compelling support for a e
irole for REST in human tumorigenesis and further vali-
date the genetic approach we have undertaken. s
sDeregulation of neuronal programs has been impli-
cated in cancer through the phenomena of para- b
pneoplastic neurological degenerations (PNDs) (Albert
and Darnell, 2004). In these diverse neurological disor- p
sders, tumors originating in nonneuronal tissues activate
expression of neural peptides that elicit an immune re- g
rsponse to the tumor as well as the host nervous sys-
tem. Although the expression of some of these neural b
Santigens is common or universal in some cancers
(breast, ovarian, small-cell lung cancers) (Albert and
lDarnell, 2004), the occurrence of PNDs in cancer pa-
tients is rare, suggesting that other factors play a role w
sin the autoimmune response. Nonetheless, aberrant ac-
tivation of neuronal gene expression raises the possi- c
gbility that regulators of neurogenesis are malfunctioning
in these tumors. To investigate this possibility, we a
dsearched for previously identified PND antigens among
known REST targets and discovered RE1 binding sites t
iin several PND antigen-encoding genes. Furthermore,
promoters of two of these PND antigens (synaptotag- f
gmin and glutamic acid decarboxylase) were recently
shown to be directly bound by REST, and, moreover, r
gtranscription of synaptotagmin was induced upon ex-
pression of a dominant-negative REST mutant similar t
fto the one we identified in tumors (Ballas et al., 2005).
This supports the hypothesis that defects in the REST c
tpathway are tied to PND pathology and tumorigenesis.
In further support of a role in tumorigenesis, REST u
cexpression was recently shown to be absent in a sub-
set of SCLC cells (Neumann et al., 2004). Additionally,
Emicroarray profiling also demonstrates downregulation
of REST expression in prostate and small cell lung can- V
cers, two malignancies that often display distinct neu- T
roendocrine phenotypes (Dhanasekaran et al., 2001; s
eGarber et al., 2001; Rhodes et al., 2004). These findings
vsuggest that REST may play a broader role in human
vmalignancies in addition to colorectal cancer.
V
s
Genetic Screening for Tumor Suppressor Pathways m
wWhile further studies will be needed to determine the
Rextent to which REST or other genes we have identified
Qare involved in human cancer, our results point to the
autility of this approach for identifying recessive cancer
p
relevant genes. Although many of the genes isolated R
via this strategy may not be frequent targets of muta- P
ption in tumors, they may nonetheless reveal novel path-
ways relevant to tumorigenesis. While we have iden-
Ctified several suppressors of cellular transformation, it
His clear that this screen was not saturated, and, conse-
2
quently, there remains significant potential for this C
method in the future discovery of SECT genes. Under- R
scoring this, the shRNA library used in our screen wasesigned to target only w9,000 genes, representing
ess than one-third of the annotated genes in the hu-
an genome. Furthermore, only one shRNA corre-
ponding to any given SECT gene was isolated in this
creen. For several of these genes, multiple corre-
ponding hairpins were present within the pSM1 library.
his suggests that many SECT candidates were not
dentified, because this library lacked a sufficiently pen-
trant shRNA to elicit the transformed phenotype. This
s not surprising, since the pSM1 library was con-
tructed before many of the parameters affecting
iRNA efficiency had emerged. For instance, the sta-
ility of siRNA ends has been shown to bias the incor-
oration of sense/antisense strands into the RISC com-
lex (Khvorova et al., 2003; Schwarz et al., 2003). Such
iRNA design “rules” improve the potency of target
ene suppression and will undoubtedly be incorpo-
ated into future generations of mammalian shRNA li-
raries, thus providing more potent tools in identifying
ECT genes.
SECT candidates identified in this screen were se-
ected for their transforming capacity in cooperation
ith the genetic milieu of TLM-HMECs (ectopic expres-
ion of hTERT, SV40 LT, and elevated endogenous
-myc expression). However, distinct classes of SECT
enes are likely to be revealed in models incorporating
lternative combinations of genetic perturbations. Ad-
itional SECT candidates may also be discovered in
ransformation models of alternative cell types, reflect-
ng the different signaling requirements in cells derived
rom various human tissues (Hamad et al., 2002; Ran-
arajan et al., 2004) or by interrogating different cancer
elevant phenotypes such as invasion, migration, or an-
iogenesis. Indeed, as in vitro models of human cell
ransformation are engineered to more accurately re-
lect the molecular changes and heterotypic cellular
omplexity found in human cancers, we anticipate that
his general strategy will enable a much more complete
nderstanding of the pathways and processes that
ancer cells usurp during tumorigenesis.
xperimental Procedures
ectors and Retroviral Production
he shRNA library constructed in pSM1 has previously been de-
cribed (Paddison et al., 2004). The PTEN shRNA-encoding pSup-
rRetro vector and the Smad7 expression plasmid were kindly pro-
ided by Dennis McCance and Xiao-Jing Wang, respectively. For
alidation experiments, shRNAs targeting ZNF134, REST, CTNND2,
DAC2P, CDH6, and TGF-βRII were designed using the RNAi de-
ign algorithm at http://katahdin.cshl.org:9331/RNAi_web/scripts/
ain2.pl. cDNAs encoding TGF-βRIICYT and TGF-βRI(T204D)
ere generously provided by Joan Massague. The Flag-tagged
EST-FS cDNA was made by site-directed mutagenesis using
uickChange (Stratagene). TGF-βRIICYT, TGF-βRI(T204D), REST,
nd REST-FS cDNAs were subcloned into the LPC retroviral vector.
WZL-neo-p85 has been previously described (Zhao et al., 2003).
etroviral supernatants were generated by transient transfection of
hoenix cells with the indicated retroviral and VSV-G-expression
lasmids and collected 48 hr posttransfection.
ell Culture
MECs expressing hTERT and SV40 LT (TLM-HMECs) (Zhao et al.,
003) were cultured in mammary epithelial growth medium (MEGM,
ambrex). Colon cancer cell lines were maintained in DMEM or
PMI supplemented with 10% FBS and 50 g/mL gentamycin. Sta-ble cell lines were generated by transduction with the indicated
Tumor Suppressor Screen
847retroviral supernatants in the presence of 8 g/mL polybrene, with
transduced cells selected for resistance to the appropriate drug:
puromycin (2.0 g/mL), neomycin (200 g/mL). Anchorage-inde-
pendent proliferation assays were performed as described (Zhao
et al., 2003), except cells were suspended in a top layer of 2.0%
methylcellulose (Sigma) in MEGM. For each assay, the average of
at least three experiments ±SD is shown. For growth curves, cells
were seeded at a density of 5.0 × 104 per well in 6-well plates
and cultured in MEGM. Cells were trypsinized and counted at the
indicated time points (in triplicate with average ±SD shown). EGF
restimulation experiments were performed as previously described
(Zhao et al., 2003).
shRNA Screen
TLM-HMECs were infected with a retroviral shRNA library con-
structed in pSM1 consisting of 20,000 shRNAs directed against
w7,500 human genes (Paddison et al., 2004) at an moi of 0.2.
Transduced cells were selected for puromycin resistance, seeded
into semisolid media (as described above) at a density of 1.0 × 105
cells per 100 mm plate (20 plates), and cultured for 3 weeks. Indivi-
dual anchorage-independent clones were isolated and expanded
on adhesive tissue culture dishes. A portion of the provirus (includ-
ing shRNA cassette) from each clone was PCR amplified from ge-
nomic DNA using primers directed against sequences within the
MSCV backbone and PGK promoter (forward, 5#-CTCCCTTTATCC
AGCCCTCAC-3#; reverse, 5#-GAGACGTGCTACTTCCATTTGTC-3#)
and sequenced using an internal primer: 5#-GAGGGCCTATTTCC
CATGAT-3#. EcoRI-XhoI fragments of the PCR fragments were also
subcloned into MCSV-SIN for validation experiments. In parallel,
anchorage-independent clones were pooled, and genomic DNA
was isolated using Qiagen DNeasy kit. PCR amplification and tran-
scription of barcodes, hybridization of custom barcode microarrays
(Agilent), and microarray analysis were performed as previously de-
scribed (Paddison et al., 2004).
Immunoblotting
Cells were lysed in HLB buffer (50 mM Tris [pH 8.0], 150 mM NaCl,
1.0% Triton-X 100, 1 mM DTT, supplemented with phosphatase-
and protease-inhibitor cocktails [Calbiochem]) for 30 min with soni-
cation. Western blotting was performed with the following anti-
bodies: αPTEN (Upstate 07-016), αTGF-βRII (Upstate 06-227 and
06-318), αRan (BD Biosciences 610340), αDDB1 (AbCam Ab9194),
αFlag (Sigma A8592), αp-465/467-Smad2 (Cell Signaling 3101),
αSmad2 (Cell Signaling 3102), αp473-Akt (Cell Signaling 9271),
αAkt (Cell Signaling, 9272), αp70-4EBP1 (Cell Signaling, 9455),
α4EBP1 (Cell Signaling, 9452), αp235/236-S6 (Cell Signaling, 2211),
αS6 (Cell Signaling, 2217), and αRest-N and αRest-C (G. Mandel).
Array-CGH Profiling and Mutation Analysis of REST
Genomic DNA extracted from 42 primary colon tumors and 38 co-
lon tumor-derived cell lines using Puregene DNA extraction (Gentra
Systems) was fragmented and random-prime labeled according to
published protocols (Aguirre et al., 2004; Bachoo et al., 2004; Pol-
lack et al., 1999) with modifications (for details, see http://genomic.
dfci.harvard.edu/array_cgh.htm). Subsequently, fluorescence ratios
of scanned images of the arrays were calculated. Raw array-CGH
profiles were processed to identify statistically significant transi-
tions in copy number using a segmentation algorithm which em-
ploys permutation analysis to determine the significance of change
points in the raw data (Aguirre et al., 2004) (Bachoo et al., 2004).
Each segment is assigned a Log2 ratio that is the median of the
contained probes. Subsequently, data was imported into the dCHIP
v1.3 software package for microarray analysis (http://www.dchip.
org/) for visualization of the segmented data. For mutation analysis,
coding exons of the REST gene were PCR amplified, purified, and
sequenced using standard conditions (primers available upon re-
quest).
Supplemental Data
Supplemental Data include one figure and one table and can be
found with this article online at http://www.cell.com/cgi/content/
full/121/6/837/DC1/.Acknowledgments
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